Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Fenimore Asset Management Inc.

Fenimore Asset Management Inc. trimmed its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 0.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 538,946 shares of the company’s stock after selling 590 shares during the quarter. Fenimore Asset Management Inc. owned about 0.36% of Henry Schein worth $37,672,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Carderock Capital Management Inc. increased its position in shares of Henry Schein by 2.4% during the second quarter. Carderock Capital Management Inc. now owns 31,435 shares of the company’s stock worth $2,197,000 after buying an additional 744 shares during the period. First Hawaiian Bank lifted its position in shares of Henry Schein by 731.5% during the second quarter. First Hawaiian Bank now owns 5,405 shares of the company’s stock valued at $378,000 after purchasing an additional 4,755 shares in the last quarter. Smith Salley & Associates bought a new position in shares of Henry Schein during the second quarter valued at about $220,000. NN Investment Partners Holdings N.V. bought a new position in shares of Henry Schein during the second quarter valued at about $687,000. Finally, Bridge Creek Capital Management LLC increased its holdings in Henry Schein by 6.8% during the second quarter. Bridge Creek Capital Management LLC now owns 39,322 shares of the company’s stock worth $2,749,000 after buying an additional 2,500 shares during the last quarter.

Shares of NASDAQ:HSIC opened at $61.54 on Friday. The company has a 50 day moving average of $67.25 and a 200 day moving average of $65.20. The stock has a market cap of $9.23 billion, a P/E ratio of 14.90, a P/E/G ratio of 2.45 and a beta of 0.84. Henry Schein, Inc. has a 12 month low of $56.58 and a 12 month high of $72.81. The company has a current ratio of 1.70, a quick ratio of 0.95 and a debt-to-equity ratio of 0.33.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.01. Henry Schein had a net margin of 4.18% and a return on equity of 16.67%. The business had revenue of $2.45 billion during the quarter, compared to analyst estimates of $2.48 billion. During the same period in the previous year, the business posted $1.04 earnings per share. Henry Schein’s revenue for the quarter was up 5.7% on a year-over-year basis. On average, equities analysts forecast that Henry Schein, Inc. will post 3.46 earnings per share for the current fiscal year.

In other news, Director E Dianne Rekow sold 3,500 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $71.18, for a total transaction of $249,130.00. Following the completion of the transaction, the director now directly owns 14,147 shares of the company’s stock, valued at approximately $1,006,983.46. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Paul Brons sold 1,758 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $70.96, for a total value of $124,747.68. Following the transaction, the director now directly owns 17,582 shares of the company’s stock, valued at $1,247,618.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,524 shares of company stock valued at $3,984,949. 1.06% of the stock is currently owned by company insiders.

HSIC has been the subject of a number of research analyst reports. Wolfe Research initiated coverage on shares of Henry Schein in a report on Thursday, May 30th. They set an “underperform” rating for the company. Craig Hallum restated a “buy” rating and set a $77.00 price objective (up previously from $72.00) on shares of Henry Schein in a report on Wednesday, May 8th. Zacks Investment Research downgraded shares of Henry Schein from a “buy” rating to a “hold” rating and set a $76.00 price objective for the company. in a report on Wednesday, June 19th. Svb Leerink restated a “market perform” rating and set a $70.00 price objective (down previously from $75.00) on shares of Henry Schein in a report on Wednesday, May 15th. Finally, William Blair downgraded shares of Henry Schein from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 7th. Seven analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $73.64.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Featured Article: What is a front-end load?

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.